Abstract| Volume 177, ISSUE 1, P45, August 2013

Cardiovascular adverse effects of injected nanocarriers: Autonomic dysregulation

      Nanocarriers can often achieve superior therapeutic outcomes for drug delivery when compared with standard drug formulations. However, concerns over their adverse effects are growing due to the correlation between exposure to nanosized particles and cardiovascular diseases. Here we examine the impact of intravenously injected drug-free nanocarriers on the cardiovasculature at both systemic and organ levels. We combine in vivo and in vitro methods to enable monitoring of hemodynamic parameters in conscious rats, assessments of the function of the vessels after sub-chronic systemic exposure to nanocarriers and evaluation of the direct effect of nanocarriers on vascular tone.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Autonomic Neuroscience: Basic and Clinical
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect